Human CellExp™ B7-2 /CD86, human recombinant
- Usually Shipped in 5 Working Days
- Storage Temperature:
- Shipping Conditions:
- Gel Pack
- Shelf Life:
- 12 months
Biomolecule/Target: B7-2 /CD86
Synonyms: CD86, B7-2, B70, CD28LG2, LAB72, MGC34413
Alternates names: CD86, B7-2, B70, CD28LG2, LAB72, MGC34413
Taglines: Involved in innate immune responses by activating NF-κB-signaling pathway
Country of Animal Origin: USA
NCBI Gene ID #.: 942
NCBI Gene Symbol: CD86
Gene Source: Human
Accession #: P42081
Source: HEK293 cells
Purity by SDS-PAGE #: ≥95%
Assay #2: N/A
Endotoxin Level: N/A
Activity (Specifications/test method): Measured by its binding ability in a functional ELISA.
Biological activity: N/A
Binding Capacity: Immobilized human CD28 at 5 μg/ml (100 μl/well) can bind human biotinylated CD86 with a linear range of 0.08 – 1.25 µg/ml.
Unit Definition: N/A
Molecular Weight: 26.8 kDa
Physical form description: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4.
Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in distilled water.
Background Information: Cluster of Differentiation 86 (CD86) also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily. It is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 and CD80 together prime T cells. B7-2 was shown to promote the generation of mature APC (antigen presenting cells) repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB signaling pathway in macrophages. CD86 is thus regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to first-line therapy.
Amino acid sequence: N/A
Handling: Centrifuge the vial prior to opening.
Usage: For Research Use Only! Not to be used in humans